Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Increased Frequency of HIV-1 Viral Load Blip Rate Observed After Switching From Roche Cobas Amplicor to Cobas Taqman Assay

22 Jun 2009

Abstract excerpt

To the Editor: HIV-1 viral load is used as a surrogate marker for antiretroviral drug therapy success. Virological success is usually defined as a having a viral load of less than 50 copies per milliliter, often referred to as “undetectable.” It has been shown that viral evolution below this limit of detection is generally too low to allow significant viral resistance to occur under a 3-drug regimen.1 Continual...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV/AIDS Research and Interventions
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19553776
DOI: 10.1097/qai.0b013e3181aa13b3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Increased Frequency of HIV-1 Viral Load Blip Rate Observed After Switching From Roche Cobas Amplicor to Cobas Taqman AssayPMID 19553776Read ↗

Comparison of the rate and size of HIV-1 viral load blips with Roche COBAS TaqMan HIV-1 versions 1.0 and 2.0 and implications for patient management.Semantic proximity Read ↗

HIV-1 viral load blips are of limited clinical significanceSemantic proximity Read ↗

HIV-1-specific CD4+ T cell responses in chronically HIV-1 infected blippers on antiretroviral therapy in relation to viral replication following treatment interruption.Semantic proximity Read ↗

Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy.Semantic proximity Read ↗

Viral load monitoring: shifting paradigms in clinical practice.Semantic proximity Read ↗

Comparative Performances of HIV-1 RNA Load Assays at Low Viral Load Levels: Results of an International CollaborationSemantic proximity Read ↗

Increased Reporting of Detectable Plasma HIV-1 RNA Levels at the Critical Threshold of 50 Copies per Milliliter With the Taqman Assay in Comparison to the Amplicor AssaySemantic proximity Read ↗

Mutations to the probe of Cobas TaqMan HIV-1 ver. 1.0 assay causing undetectable viral load in a patient with acute HIV-1 infection.Semantic proximity Read ↗

Single-Point Mutations Causing More than 100-Fold Underestimation of Human Immunodeficiency Virus Type 1 (HIV-1) Load with the Cobas TaqMan HIV-1 Real-Time PCR AssaySemantic proximity Read ↗

Evaluation of an Upgraded Version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Test for HIV-1 Load QuantificationSemantic proximity Read ↗

Brief Report: Toll-like Receptor 9-1635A/G Polymorphism Is Associated With HIV-1 Rebound After Four Weeks of Interruption of Antiretroviral Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.